Marinus Pharmaceuticals, Inc.

$0.55+0.00%(+$0.00)
TickerSpark Score
60/100
Mixed
73
Valuation
60
Profitability
50
Growth
68
Health
50
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MRNS research report →

52-Week Range3% of range
Low $0.22
Current $0.55
High $10.50

Companymarinuspharma.com

Marinus Pharmaceuticals, Inc. , a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.

CEO
Scott N. Braunstein
IPO
2014
Employees
165
HQ
Radnor, PA, US

Price Chart

-78.26% · this period
$2.55$1.39$0.23Feb 09Aug 12Feb 11

Valuation

Market Cap
$30.37M
P/E
-0.21
P/S
0.98
P/B
1.76
EV/EBITDA
-0.16
Div Yield
0.00%

Profitability

Gross Margin
93.76%
Op Margin
-424.30%
Net Margin
-456.31%
ROE
-213.02%
ROIC
-89.82%

Growth & Income

Revenue
$30.99M · 21.63%
Net Income
$-141,405,000 · -613.59%
EPS
$-2.63 · -415.69%
Op Income
$-131,485,000
FCF YoY
-3.02%

Performance & Tape

52W High
$10.50
52W Low
$0.22
50D MA
$0.43
200D MA
$1.06
Beta
1.26
Avg Volume
1.81M

Get TickerSpark's AI analysis on MRNS

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

DateInsiderTypeShares
Feb 7, 25Ezickson Elansell8,600
Feb 11, 25Ezickson Elansell10,450
Feb 11, 25Ezickson Elansell12,375
Feb 11, 25Ezickson Elansell16,500
Feb 11, 25Ezickson Elansell20,900
Feb 11, 25Ezickson Elansell16,200
Feb 11, 25Ezickson Elansell25,000
Feb 11, 25Ezickson Elansell2,300
Feb 7, 25Fischer Seth H. Z.sell12,707
Feb 11, 25Fischer Seth H. Z.sell16,200

Our MRNS Coverage

We haven't published any research on MRNS yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate MRNS Report →

Similar Companies